Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 265

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 265
---
2020 and on the Board of Directors of Calithera Biosciences, Inc. from
2020 to 2023. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University-San Luis Obispo and a master’s degree in Business Administration from the Fuqua School of
Business at Duke University. Our board of directors believes that Mr. Garland’s extensive leadership experience in the healthcare industry and his service as a public company director qualify him to serve on our board of directors.

Rajul Jain, M.D. has served as a member of our board of directors since September 2023. Since May 2019, Dr. Jain has been a partner at
Vida Ventures, where he currently is a Managing Director. Dr. Jain previously served as Vice President at Kite Pharma, Inc. Previously, Dr. Jain was at Amgen, Inc. where his last role was Global Development Lead. There he oversaw the
development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&D pipeline including regulatory approvals of Xgeva and Prolia. Dr. Jain also serves as a board member of
Capstan Therapeutics, Inc., InduPro, Inc., Locanabio, Inc., A2 Biotherapeutics, Inc., Quanta Therapeutics, Inc., and Third Arc Bio, Inc. Dr. Jain completed his B.A. in Chemistry and Biochemistry at Rice University, and M.D. and Internal
Medicine internship and residency at UT Southwestern Medical School, where he was a Howard Hughes Fellow. He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at M.D. Anderson Cancer Center, where
he was chief fellow. Our board of directors believes that Dr. Jain’s financial expertise and investment experience in the life sciences industry provides him with the qualifications to serve on our board of directors.

Rebecca Luse has served as a member of our board of directors since August 2023. Since January 2021, Ms. Luse has served as Principal of
Deep Track Capital. Ms. Luse previously served as Principal of New Leaf Venture Partners. Previously, she worked on the sell side at both Jefferies and Piper Jaffray, covering biotechnology and specialty pharmaceuticals companies. Ms. Luse
started her career as an investment banking analyst in the health care group of Bank of America and as a venture capital associate at Bay City